Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201601-04 Development of Selective Insulin Receptor Agonist Aptamer(Metabolic Disorders, Protein) [12.29.2016]

PRINT

Development and Market Objectives

To develop and optimize a type 2 diabetes drug with selective insulin receptor agonist aptamers that can replace insulin or reduce insulin usage, which can reduce insulin-related side effects.

 

Unmet Medical Need & Target Patients

Type 2 diabetes patients are exposed to side effects such as increased insulin resistance, cancer risk, CVD risk, weight gain, and hypoglycemia due to long-term administration of insulin. Therefore, there is a strong need for therapeutic agent that can unburden patients by reducing the number of insulin treatments.

 

Status

- Secured two kinds of initial effective substance which can selectively bind to insulin receptor and promote phosphorylation

- Sequence optimizing in progress for the initial compounds

 

Intellectual Property

- Completed Korean patent application for early active substances (2015)

- Completed PCT application for early active substances (2015)

 

Competitive Advantages

A48 and A62 are agonist aptamer which bind to insulin receptors(IR) and induce phosphorylation. They are highly selective for IR and unlike insulin, they do not bind to IGF-1R. A48 and A62 induce glucose uptake, but they have a selective function that does not induce cell growth, thus reducing cancer risk and CVD risk. Selected phosphorylation of IR by aptamers opens up to the possibility of overcoming the effects of PTP1b, one of the mechanisms of insulin resistance. In addition, the two aptamers have lower inhibitory effects on lipolysis than insulin, so they can lower the side effects of insulin-induced weight gain, which is expected to play an effective role in the treatment of diabetes.

 

Indication

Diabetes

Research Period

2016.12.9-2018.10.8

Company

aptamer sciences Inc.

Developmental Stage

Optimization

Additional Information

Contact Information

Contact
Address Company Name: aptamer sciences Inc.
WebSite Homepage: http://www.aptsci.com Contact Person: Sung Ho, Ryu
E-mail: sungho@postech.ac.kr Contact: 82-54-279-2292

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code